Investor Presentation

September 2025

BioStem TECHNOLOGIES

Forward Looking Statements

This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, certain statements, estimates and projections provided by BioStem Technologies, Inc. (the “Company”, “us” or “we”) with respect to anticipated future performance. Words such as “expects,” anticipates,” “intends,” “plans,” “likely,” “will,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward looking statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore such statements included in this presentation may not prove to be accurate. Forward-looking statements in this presentation relate to the our: ongoing commitment to deliver advance wound care solutions to improve the quality of life for patients; expectations regarding growth and the related driving factors, including with respect to AmnioWrap2; expectations regarding the innovation of new placental platform technologies; expectations regarding intellectual property values and uses; expectations regarding our relationship with Venture Medical; expectations regarding ongoing and future clinical trials, as well as our ability to demonstrate BioREtain’s competitive advantages; estimates and expectations regarding the total addressable wound market; strategic growth initiatives, including but not limited to strategic acquisitions, expansion into new markets and expansion of our commercial team; expectations regarding further penetration of current markets; the opportunity for leverage on sales and marketing expenses; ability to capitalize and report clinically significant data over our competitors; and expectations regarding future operations, financial positions, estimated revenue, forecasts, prospects and plans.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. The following is a list of risks, among others, that could cause actual results to differ materially from those contemplated by the forward-looking statements: the risk that the Company may not be able to achieve or maintain profitability in the future; the risk that the Company has derived the majority of our revenue from a distribution agreement; the risk that a material amount of revenues and accounts receivable are concentrated in one or more customers, and that if the Company loses or experiences a significant reduction in sales, the Company’s revenues may decrease substantially and materially affect the Company’s results of operations and financial condition; the risk that the Company will be unable to maintain its use of intellectual property; the Company’s ability to convince physicians that the products are safe and effective alternatives to existing treatments and that the Company’s products should be used in their procedures; the risk that the Company will be unable to maintain adequate levels of reimbursement from public and private insurers and health systems which may result in changes to the ways in which the Company’s products are reimbursed in various sites of service and, as a result may adversely impact the Company’s financial results; the risk that the Company will be unable to produce sufficient data to support coverage of our products under the finalized LCDs or otherwise satisfy any regulatory requirements needed to ensure our products are eligible for Medicare reimbursement; the risk that the FDA may in the future determine that certain products that are, or are derived from, human cells or tissues, do not qualify for regulation solely under Section 361 of the Public Health Service Act, and may require that the Company revise its labeling and marketing claims for these products or require the Company to suspend sales of such products until FDA pre-market clearance or approval is obtained, either of which could adversely affect the Company’s business, results of operations, and financial condition; the risk that the rate of reimbursement and coverage for the purchase of the Company’s products by government and private insurance may change; and the risk that the Company may not meet the listing standards of the Nasdaq Stock Market.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Preliminary Results

The Company's financial results included in this presentation are preliminary, unaudited and subject to finalization of BioStem’s audited financial statements for the year ended December 31, 2024 and resolution of all SEC comments on the Form 10 registration statement that BioStem filed with the SEC in connection with its planned uplist to Nasdaq. These financial results should not be viewed as a substitute for final reviewed results prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preliminary financial results represent management estimates that constitute forward-looking statements subject to risks and uncertainties. As a result, the preliminary financial results and other information provided herein may materially differ from the actual results that will be reflected in the consolidated audited financial statements for the year ended December 31, 2024 and unaudited financial statements for the first and second quarters of 2025 when they are completed and publicly disclosed. The Company undertakes no obligation to update or supplement the information provided herein until it reports its final audited financial results for the year ended December 31, 2024 and unaudited financial results for the first and second quarters of 2025.

Our Mission

To create and deliver the most advanced wound healing technologies in the world

Our Vision

Our vision is to pioneer advanced healing solutions and improve our patients' quality of life through an unwavering commitment to innovation

BioStem TECHNOLOGIES

Corporate Highlights

Profitable and scalable MedTech company

Multi-Billion Dollar Market Opportunity*

- $11.3B US advanced wound care market
- >7M Medicare patients with chronic non-healing wounds

Proven Proprietary BioRetain® Technology

- Optimized retention of natural amniotic tissue structure and molecular composition
- Proven superiority over competition
- 55 issued patents, 53 pending

Broad Product Portfolio

- 5 placental-derived allograft products
- Treating chronic wounds – DFU, VLU, PU

Strategic Sales & Marketing Agreement

- Exclusive partnership with Venture Medical
- Venture is an industry leading wound care distributor with 150+ reps nationwide

Advanced Manufacturing Expertise

- Scalable 6,100 sq ft facility
- Currently processing 30k sq cm monthly
- OEM capability for private label marketers

Transformative Financial Results for 2024*

- **Revenue:** $301.8M
- **aEBITDA:** $39.4M
- **Cash:** $30.8M (As of 6/30/25)

BioStem TECHNOLOGIES

- Wound Care Market data from SmartTrak Q424/FY24 Advanced Wound Care Market report, May 2025.
- Chronic wound size – 2-2.5% of the U.S. population. https://pubmed.ncbi.nlm.nih.gov/37756368/#:~:text=Chronic%20wounds%20impact%20the%20quality,population%20of%20the%20United%20States.

- Results are unaudited and are subject to resolution of all SEC comments to the Company's Form 10 and completion of the audit of the Company's 2024 annual financial statements.

Multi-Billion Dollar Market Opportunity

BioStem TECHNOLOGIES

Chronic Non-healing Wounds Impact Millions of Patients Annually

PU, DFU and VLU represent 82% of chronic wounds



PU
Pressure Ulcers

Underlying pathology:
Tissue necrosis due to sustained pressure

Affect:
Bony prominence: mostly sacral, ischial, trochanteric

Incidence:
3M+ new US cases annually*



DFU
Diabetic Foot Ulcers

Underlying pathology:
Diabetes (Type I/II)

Affect:
Mostly bottom of foot

Incidence:
2.2M+ new US cases annually*



VLU
Venous Leg Ulcers

Underlying pathology:
Chronic venous insufficiency

Affect:
Lower leg or ankle

Incidence:
1.5M+ new US cases annually*

7M+ Chronic Wound Patient Breakdown



Complications: Infection, sepsis, amputation, pain, disability, death

Societal Impact: Substantial healthcare burden, low quality of life

BioStem TECHNOLOGIES

- **Wound Care Market data from SmartTrak Q424/FY24 Advanced Wound Care Market report, May 2025.**

Sites of Care for Wound Treatment

Sites of Care



BioStem plans to expand focus beyond Mobile Health and Private Office into:

- **Ambulatory Surgery Center (ASC)**
- **Hospital Outpatient Department (HOPD)**
- **Veteran Affairs (VA)**

BioStem TECHNOLOGIES

BioStem is Addressing a Multi-Billion Dollar Opportunity within the Chronic Wound Market

Steady US growth opportunity





- Chronic wound size – 2-2.5% of the U.S. population. https://pubmed.ncbi.nlm.nih.gov/37756368/#:~:text=Chronic%20wounds%20impact%20the%20quality,population%20of%20the%20United%20States.
- Diabetes source: Projection of diabetes morbidity and mortality till 2045 in Indonesia based on risk factors and NCD prevention and control programs | Scientific Reports (nature.com)
- PAD 2020-2030: The Current U.S. Prevalence of PAD | Vascular Disease Management (hmpgloballearningnetwork.com)
- Wound Care Market data from SmartTrak Q424/FY24 Advanced Wound Care Market report, May 2025.

BioStem TECHNOLOGIES

Proven Proprietary BioRetain® Technology Powers Commercial Portfolio

BioStem TECHNOLOGIES

Clinical Outcomes

BioRetain® Vendaje AC outperforms in real-world outcomes

Fewer Applications



Faster Closure



BioStem TECHNOLOGIES

Assessing Treatment Efficiency in Diabetic Foot Ulcers: Processing for Retention* Versus Lamination: A Retrospective Analysis. Zwelithini Tunyiswa, Robert Frykberg, Wendy W Weston, Scientific Poster.

BioRetain® Benefits

- *Fewer applications to achieve closure*
- *Faster time to wound closure*
- *Cost savings to the healthcare system*

BioRetain® Optimizes Retention of Natural Tissue Properties

Demonstrated Superiority Over Competitors



Anti-inflammatory Cytokines
Modulate inflammation by suppressing pro-inflammatory molecules



Growth Factors
Promote tissue regeneration and reduce scarring



Hyaluronan
Promotes stem cell proliferation



Extracellular Matrix
Provides a scaffold for new tissue generation

BioStem TECHNOLOGIES

- Standardized reporting of amnion and amnion/chorion allograft data for wound care. Sabol, TJ, Tran, GS, Matuszewski, J, Weston, W. Health Science Reports, Aug. 2022.
- Competitors 1, 2 and 4 are all dehydrated amniochorion products.

Randomized Controlled Trials Underway

Demonstrating superiority of BioRetain® over standard of care

Product	Study	Wound Type	Study Design	Primary Outcome	Status	Readout Data
Vendaje AC®	BR-AC-DFU-101	**Diabetic Foot Ulcers**	71 patients across 10 sites *NCT06511596*	**Complete closure at 12 weeks**	Enrollment complete	**~ Q4 ’25**
	BR-AC-VLU-101	**Venous Leg Ulcers**	60 patients across 10 sites *NCT06811909*	**Complete closure at 12 weeks**	In process	**~ Q1 ’26**
Vendaje®	BR-AM-DFU-101	**Diabetic Foot Ulcers**	60 patients across 10 sites *NCT06565156*	**Complete closure at 12 weeks**	In process	**~ Q1 ’26**

Additional retrospective studies underway to demonstrate real-world outcomes with BioRetain

Partnering with Venture Medical to launch exclusive patient registry

Drive increased adoption and support market expansion efforts

BioStem TECHNOLOGIES

Processing Advanced Allografts

BioRetain® is the underlying technology used in BioStem allografts

Placental Donation

Expectant mom introduced to donation and recovery program

Mom consents to donate and completes FDA donor screening assessment

Delivery of healthy full-term baby via cesarian in the U.S

Donated placental tissue recovered

Proprietary Technology

Microbiology testing of donor tissue

Proprietary processing and terminal sterilization

4-Year shelf-stable packaged product

58 issued patents

68 pending

BioStem's patented and differentiated process preserves the natural structural and molecular integrity of the amniotic tissue.

BioStem TECHNOLOGIES

World-Class Manufacturing

AATB® accredited, cGTP facility

- State of the art, vertically integrated manufacturing facility
- Currently processing 30k sq cm monthly
- Additional capacity available to meet future demand
- 6,100 sq ft dedicated area
- 3,000 sq ft ISO clean room space
- Located in Pompano Beach, FL

BioStem TECHNOLOGIES

Commercial Portfolio

Powered by BioRetain®

Commercialized Via 361 HCT/P Regulatory Pathway

BioStem TECHNOLOGIES

Evolving Reimbursement Framework

Strategic Priorities Position BioStem for Market Share Gains

2025

Payment methodology incentivizes utilization of higher priced products

HOPD	ASC	Physician Office
$1,780	$860	ASP
Bundled Payment	Bundled Payment	CPT & ASP

- >200 skin substitutes with Q codes and new products continue to be added
- New pricing published every 90 days

2026

CMS proposed pricing changes to Physician Fee Schedule (PFS) and Outpatient Prospective Payment Service (OPPS)

HOPD	ASC	Physician Office
Est. $800	Est. $400	Est. $80
Est. $125.38 per sq. cm	Est. $125.38 per sq. cm	Est. $125.38 per sq. cm

- Expanding body of clinical evidence supports adoption of BioRetain® allografts
- Commercial expansion focused on addressing alternative sites of care
- 98% gross margins support absorption of potential pricing pressure*

* Results are unaudited and are subject to resolution of all SEC comments to the Company's Form 10 and completion of the audit of the Company's 2024 annual financial statements.

Strategic Commercial Initiatives

BioStem TECHNOLOGIES

Strategic Priorities

Sustained growth driven by core initiatives

Drive Growth

- Expand hybrid commercial team – indirect and direct
- Increase penetration of office and mobile markets
- Establish foundation for 2026 expansion into hospital market with existing products
- Increase patient access to existing products

Diversify Portfolio

- Innovate new technologies in placental platform
- Strategic acquisitions
  - Synergistic patents
  - Alternative biologic technologies
  - Advanced wound care – external devices
  - Products addressing alternative site of care markets

Publish Data

- Complete RCTs to demonstrate clinical efficacy
- Expand technical data demonstrating superiority versus competitors
- Generate retrospective real-world data

BioStem TECHNOLOGIES

BioStem Technologies & Venture Medical

Exclusive sales & marketing agreement



Venture Medical

More than 150 sales representatives nationwide

Venture OneView – proprietary platform to manage chronic wound patients from insurance verification through payment

Strong presence in fastest growing segments of wound care market - **office and mobile**

BioStem TECHNOLOGIES

Financial Highlights

Strong Revenue Trend

*Transformative 2024 growth**

Key Milestones

3Q 2023
Initiated Venture Medical Partnership

4Q 2023
AmnioWrap2™ Coverage in All MAC Regions

4Q 2024
Vendaje AC® Coverage in All MAC Regions



BioStem TECHNOLOGIES

* Results are unaudited and are subject to resolution of all SEC comments to the Company's Form 10 and completion of the audit of the Company's 2024 annual financial statements.

Recent Financial Highlights

	2024 FISCAL YEAR REVENUE* $302 M				FIRST HALF 2025 REVENUE* $122 M	
	1Q 2024	2Q 2024	3Q 2024	4Q 2024	Q1 2025	Q2 2025
Revenue	$41.9M	$74.5M	$82.6M	$102.9M	$72.5M	$49.3M
Gross Margin	95%	95%	95%	97%	99%	99%
S&M % of sales	73%	79%	79%	79%	80%	80%
aEBITDA	$7.9M	$10.0M	$10.4M	$11.1M	$7.8M	$2.5M

- *Results are unaudited and are subjected to resolution of all SEC comments which may cause actual results to differ materially from those presented in this presentation.*

Highlights:

- Profitable business and strong financial position
- Industry leading gross margins
- Opportunity for substantial leverage on S&M expenses
- **Cash:** $30.8M (As of 6/30/25)

2024:

- **Record revenue significant** growth to $302M
- **Record bottom line** generated aEBITDA $39.4M

2Q2025:

- Revenue impacted by temporary exclusion from preliminary ASP list

BioStem TECHNOLOGIES

Positioned for Success

BioStem TECHNOLOGIES

Management Team

Accomplished team with deep industry experience

Jason Matuszewski
LSSBB

Chief Executive Officer

HUSCO INTERNATIONAL · Nemak Innovative Lightweighting · ATI · SCJohnson

Andrew VanVurst
CTBS

Chief Operating Officer

Brandon Poe

Chief Financial Officer

MIDI HEALTH · genome MEDICAL · illumina

Michael Fortunato
CPA

Chief Accounting Officer

facebook · Upwork · U.S. Securities and Exchange Commission

Barry Hassett

Senior Vice President of Marketing

BioTissue · PROXIMA THERAPEUTICS, INC. · CAIRE Niterra Group

Morgan Kim

Vice President of Corporate and Legal Compliance

COOK MEDICAL

Wendy Weston
PhD, CTBS

Vice President of R&D

VIVEX BIOLOGICS · MIAMI

Noah Agron

Vice President Corporate Finance and Strategy

BLACK BROOK CAPITAL MANAGEMENT · GILFORD SECURITIES

BioStem TECHNOLOGIES

Well-Positioned to Capitalize on Opportunities in the Wound Care Market

- Large, growing market with significant adjacent opportunities
- Expanding clinical evidence and commercial footprint to drive market penetration
- Diversifying commercial product portfolio
- Strong financial position to support growth initiatives

In Relentless Pursuit of Healing™

Thank you!

BioStem TECHNOLOGIES